Clinical trials: T-Cell Lymphoma
ALK-activated Tumors
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose…
- Trial name
- NCT01742286
- Testing
- Ceritinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent
A Phase II Study of Doxycycline in Relapsed NHL
The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent, Lymphoma, Follicular, Marginal Zone B-Cell Lymphoma
- Trial name
- NCT02086591
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Cutaneous T-cell Lymphoma, Mycosis Fungoides
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
The purpose of this trial is to determine if combination therapy with rosiglitazone and bexarotene might have a synergistic effect in the treatment of patients with CTCL.
- Conditions
- Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT00178841
- Testing
- Rosiglitazone and Bexarotene
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
- Trial name
- NCT00355472
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Mycosis Fungoides, Recurrent Mycosis Fungoides
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types…
- Conditions
- Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome
- Trial name
- NCT04541017
- Testing
- Biospecimen Collection, Computed Tomography, Magrolimab
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Adult T-cell Leukemia-Lymphoma, ATLL
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
The investigators propose to use Belinostat in combination with AZT as consolidation therapy for the treatment of ATLL.
- Trial name
- NCT02737046
- Testing
- Belinostat, Zidovudine, Interferon-Alfa-2b
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Miami
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Background: Mature T-cell malignancies (TCMs) are a rare group of cancers that usually do not have effective treatments or cures. Because of this, participants with TCMs often relapse and have a poor overall prognosis.
- Conditions
- Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
- Trial name
- NCT04447027
- Testing
- Romidepsin, Lenalidomide, CC-486 (5-azacitidine)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia)
Stem Cell Transplantation for Patients With Cancers of the Blood
This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood.
- Conditions
- CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia
- Trial name
- NCT00467961
- Testing
- Miltenyi system
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Kidney Cancer, Leukemia
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity
- Trial name
- NCT00365768
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Columbia University
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab.
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04312841
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML)
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
- Conditions
- Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma
- Trial name
- NCT03615105
- Testing
- Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center